Abstract
Aim With increasing global use of hotel-based quarantine as part of COVID-19 border control efforts, we aimed to assess its risk of failure.
Methods We searched official websites in both Australia and New Zealand (NZ) to identify outbreaks and border control failures associated with hotel quarantine (searches conducted up to 12 February 2021). We used two denominators: a) the estimated number of travelers who went through these facilities during the 2020 year up to 31 January 2021; and b) the equivalent number of SARS-CoV-2 positive people who went through these facilities.
Results Up to 31 January 2021, Australia had seven failures with one causing over 800 deaths and six resulting in lockdowns. In NZ there were nine failures, with one causing an outbreak with three deaths, and also a lockdown. The overall failure risk for those transiting quarantine was estimated at one failure per 20,702 travelers and one failure per 252 SARS-CoV-2 positive cases (both countries combined). At the country level, there were 15.5 failures per 1000 SARS-CoV-2 positive cases transiting quarantine in NZ (95%CI: 5.4 to 25.7), compared to 2.0 per 1000 SARS-CoV-2 positive cases in Australia (0.5 to 3.5) – a greater than seven-fold difference in risk. Approaches to infection control and surveillance in hotel quarantine were found to vary widely by country and by state/territory.
Conclusions There appears to be a notable risk of failure with the use of hotel quarantine in these two countries. The large variation in infection control practices suggests opportunity for risk reduction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Prof Baker and Dr Kvalsvig received funding support from the Health Research Council of New Zealand (20/1066). Dr Grout, Ms Katar, Dr Ait Ouakrim, Dr Summers, Prof Blakely, and Prof Wilson did not have external funding support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There was no requirement for ethics review as the study only utilised publicly available anonymised data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets analyzed during the current study were derived from public resources available from the New Zealand Ministry of Business Innovation & Employment, the New Zealand Ministry of Health. the Australia Bureau of Statistics. and the Australian Department of Health.
https://www.health.gov.au/resources/collections/coronavirus-covid-19-common-operating-picture
